Methylphenidate Explained: Mechanism, Forms and Common Effects

Methylphenidate is the most prescribed stimulant for ADHD in the UK and the first-line stimulant for children and adolescents under NICE NG87 ^[1]. This article explains how it works, the UK formulations and their release profiles, the common effects to expect, and how the formulation choice fits the shape of a school or working day.

How methylphenidate works

Methylphenidate works mainly by blocking the dopamine transporter and the noradrenaline transporter, the two proteins that recycle these neurotransmitters out of the synapse after they have done their signalling ^[5]. With the transporters partially blocked, dopamine and noradrenaline remain in the synapse for longer and the signals they carry land more reliably. The effect is concentrated in the prefrontal cortex and the striatal circuits that are central to attention, working memory, motivation and the regulation of action.

Unlike the amphetamine class, methylphenidate does not significantly increase the release of dopamine and noradrenaline from the presynaptic neuron at therapeutic doses ^[2]. This is the main pharmacological difference between the methylphenidate and amphetamine families and is one reason patients can respond well to one but not the other.

Methylphenidate is licensed in the UK from age 6 for ADHD when remedial measures alone have proved insufficient ^[2]. The Cortese 2018 network meta-analysis in the Lancet Psychiatry, the largest available synthesis of ADHD medication trials, identified methylphenidate as the best-tolerated first-line option in children and adolescents ^[4].

The UK formulations

UK methylphenidate comes in two broad shapes: immediate-release and modified-release. The modified-release brands have different release profiles, which matters in practice.

Immediate-release methylphenidate

The shortest-acting option. Effect onset within around twenty to thirty minutes and duration of approximately three to four hours ^[2]. Taken two or three times across the day, often morning, lunchtime and mid-afternoon. Useful where flexibility is needed, for the very fine-grained adjustment that comes early in titration, or as a top-up alongside a modified-release brand for the late afternoon.

Concerta XL

A modified-release tablet using an osmotic delivery system. Designed to release methylphenidate progressively across approximately twelve hours from a single morning dose ^[2]. The release profile rises steadily through the day, which suits a school or working day that runs through to the early evening. Tablet is non-divisible because of the osmotic mechanism.

Equasym XL

A modified-release capsule with a faster initial release followed by a slower second phase. Total duration approximately eight hours ^[2]. Often chosen where a strong morning effect is needed and where afternoon cover is less essential, or for children whose school day ends early.

Medikinet XL

A modified-release capsule with a similar two-phase release to Equasym XL but a slightly different ratio. Duration approximately eight hours ^[2]. Taken with food, which the patient information leaflet specifies.

Xaggitin XL and Delmosart

Modified-release tablets formulated to match the Concerta XL release profile ^[2]. They are listed in the BNF as alternatives where Concerta XL is unavailable or where a different generic supply is appropriate. Brand interchangeability is a prescribing decision rather than a patient one; pharmacists will not switch brand without prescriber authorisation.

The practical choice between modified-release brands rests on the shape of the day. A working adult with a long, demanding afternoon often suits Concerta XL, Xaggitin XL or Delmosart. A child whose attentional needs are concentrated in the school morning often suits Equasym XL or Medikinet XL. The picture is individualised and refined across the first weeks of ADHD medication and titration with NeuroFX.

What to expect from a methylphenidate trial

Specific doses are a prescribing decision and depend on age, weight, formulation and clinical picture. What is useful to know is the shape of a trial.

For most patients, the first ten to fourteen days bring a settling-in period where the body adjusts to the medication. Common early effects include reduced appetite at lunchtime, a transient headache, mild dry mouth and some difficulty getting to sleep ^{[2, 3]}. Most of these settle within a fortnight. A clear, reliable improvement in attention, task initiation and emotional regulation typically becomes evident on the second or third dose increase rather than the first.

NICE NG87 sets the formal review point at around six weeks after a steady working dose is reached ^[1]. Most clinicians review more frequently than that during active titration. The detail of what to expect across the months is in a calm guide to the first six months of titration.

Common effects across longer-term use

Once a working dose is stable, the side-effect profile usually settles into a small set of effects that the patient can describe in concrete terms. The most commonly reported are ^{[2, 3]}:

• Reduced appetite, particularly at lunchtime
• Some difficulty getting to sleep, especially if the dose is taken late
• A modest rise in resting heart rate
• A small rise in blood pressure
• Occasional headache
• Dry mouth
• Mild irritability or low mood as the dose wears off (often called rebound)
• In children, slower growth in weight and sometimes height; usually returns to expected trajectory after stopping

A small minority of patients experience tics, sustained low mood, or significant cardiovascular changes; these are flagged in the BNF as effects that warrant clinician review ^[2]. They are uncommon, but they do happen, and they warrant reporting rather than waiting.

When methylphenidate is not the right fit

Around a third of patients find that methylphenidate, despite an adequate trial, is not the right stimulant for them ^[4]. Reasons include incomplete benefit, side effects that do not settle, or a release profile that does not match the working day even after a brand switch. The usual next step under NICE NG87 is a trial of the amphetamine class (lisdexamfetamine, sometimes dexamfetamine), which has a different pharmacology and often suits patients who did not get on with methylphenidate ^[1]. Non-stimulant options (atomoxetine, guanfacine) are alternatives where stimulants are unsuitable.

Practical notes

• Methylphenidate is a Schedule 2 controlled drug. Prescriptions are typically for up to 28 days, with specific legal requirements that affect supply and travel. The controlled drugs article in this library covers the detail.
• Brand interchangeability is restricted in NHS prescribing. The BNF advises that modified-release brands should be prescribed by brand name rather than as generic methylphenidate, because the release profiles are not directly interchangeable ^[2].
• Missed doses are common during titration. A missed morning dose taken later in the day can disrupt sleep; the usual advice is to skip the missed dose rather than catch up unless your prescriber has said otherwise.
• Alcohol is not contraindicated with methylphenidate, but heavy drinking interacts with the cardiovascular effects and is worth a separate conversation with the prescriber.

What this means in practice

• Methylphenidate is well evidenced, well tolerated in most patients, and the usual first stimulant tried in children and adolescents.
• The choice between immediate-release and modified-release brands is shaped by the working or school day, not by which brand is better.
• The starting dose is almost never the final dose; expect three months of structured adjustment with regular review.
• Most early side effects settle within two weeks. Persistent side effects are a conversation, not a reason to stop on your own.
• If methylphenidate does not suit, the chance of an amphetamine-class stimulant suiting is high.

When to speak to a professional

Speak to your GP, your private prescriber or NHS 111 if a new symptom appears that worries you, if your blood pressure or heart rate feels noticeably different, or if changes to mood, sleep or appetite are not settling. Seek urgent help via 999 or A&E for chest pain, shortness of breath, fainting or any acute mental health crisis. NeuroFX offers private adult ADHD assessment and paediatric ADHD assessment for children aged 6 and upwards, including specialist initiation and titration of methylphenidate, where the NHS waiting list is not workable.

Sources

1. NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
2. British National Formulary. Methylphenidate hydrochloride. https://bnf.nice.org.uk/drugs/methylphenidate-hydrochloride/
3. British National Formulary for Children. Methylphenidate hydrochloride. https://bnfc.nice.org.uk/drugs/methylphenidate-hydrochloride/
4. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
5. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews. 2021;128:789-818.